Hypera S.A. (BST:HM6A)

Market Cap	2.75B +15.7%
Revenue (ttm)	1.44B +29.0%
Net Income	279.75M +108.4%
EPS	0.44 +108.5%
Shares Out	n/a
PE Ratio	9.82
Forward PE	8.49
Dividend	0.16 (4.18%)
Ex-Dividend Date	Apr 6, 2026

Volume	n/a
Average Volume	38
Open	3.700
Previous Close	3.700
Day's Range	3.620 - 3.820
52-Week Range	2.980 - 4.700
Beta	n/a
RSI	45.48
Earnings Date	Apr 28, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 10,564
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: HM6A

Financial Performance

In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.

Financial numbers in BRL